Article

Topical Kunzea Oil Does Not Benefit Patients with Psoriasis

Author(s):

Researchers found that adding kunzea oil to topical psoriasis treatments with liquor carbonis detergens (LCD) and salicylic acid did not improve the irritating skin condition.

Researchers found that adding kunzea oil to topical psoriasis treatments with liquor carbonis detergens (LCD) and salicylic acid did not improve the irritating skin condition.

Jackson Thomas, PhD, University of Canberra, Australia, and colleagues conducted a study and published the results in the Journal of Clinical Pharmacy and Therapeutics.

Thomas and team randomized a total of 30 patients (average age of 52.8 years) with mild-to-moderate psoriasis to receive ointment and/or scalp lotion with 20% kunzea oil or receive placebo medication lacking kunzea oil.

They reported that the test and placebo groups both exhibited a significant improvement in Psoriasis Area and Severity Index Scores (PASI) following eight weeks of treatment.

In other words, there appeared to be no tangible difference in outcomes among the patient cohort.

The researchers concluded, “The inclusion of kunzea oil made no difference to the efficacy of topical formulations containing LCD and salicylic acid for the treatment of psoriasis.”

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.